| |
Article Title |
Author(s) |
Pages |
|
|
|
Cover
|
|
OFC
|
|
|
|
Masthead
|
|
IFC
|
|
| Current Clinical Practice |
| |
Article Title |
Author(s) |
Pages |
|
|
|
A Wealth of New Options: A Case Presentation of the Management of Castration-Recurrent Prostate Cancer
|
Douglas F. Beach,
Robert A. Somer,
Jean Hoffman-Censits,
Jianqing Lin,
Yu-Ning Wong,
Elizabeth Plimeck,
Gary Hudes,
David Vaughn,
Guy T. Bernstein,
Gloria J. Morris
et al.
|
1-8
|
|
| Molecular Pathogenesis of Hematologic Malignancies |
| Jaroslaw P. Maciejewski, MD, PhD, and Torsten Haferlach, MD, Guest Editors |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Introduction: Molecular Pathogenesis of Hematologic Malignancies
In addition to activating oncogenic mutations, deletions of chromosomal material, hypomorphic/inactivating mutations and aberrant promoter silencing of tumor-suppressor genes (TSG) have been recognize...
|
Jaroslaw P. Maciejewski,
Torsten Haferlach
|
9-12
|
|
|
|
Single-Nucleotide Polymorphism Array Karyotyping in Clinical Practice: Where, When, and How?
Single-nucleotide polymorphism array (SNP-A) karyotyping is a new technology that has enabled genome-wide detection of genetic lesions in human cancers, including hematopoietic neoplasms. Taking advan...
|
Aiko Sato-Otsubo,
Masashi Sanada,
Seishi Ogawa
|
13-25
|
|
|
|
Integration of Next-Generation Sequencing Into Clinical Practice: Are We There Yet?
Next-generation sequencing (NGS) platforms have evolved to provide an accurate and comprehensive means for the detection of molecular mutations in heterogeneous tumor specimens. Here, we review potent...
|
Alexander Kohlmann,
Vera Grossmann,
Torsten Haferlach
|
26-36
|
|
|
|
Array-Based Cytogenetic Approaches in Acute Myeloid Leukemia: Clinical Impact and Biological Insights
Conventional cytogenetic studies have shown that the clinical and biological diversity of acute myeloid leukemia (AML) can be attributed, in part, to distinct chromosome aberrations, several of which ...
|
Lars Bullinger,
Stefan Fröhling
|
37-46
|
|
|
|
Acute Lymphoblastic Leukemia: Monitoring Minimal Residual Disease as a Therapeutic Principle
Measurement of submicroscopic (minimal) levels of residual disease (MRD) can be used to monitor treatment response much more precisely than morphological screening of bone marrow slides. Several studi...
|
Monika Brüggemann,
Nicola Gökbuget,
Michael Kneba
|
47-57
|
|
|
|
Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated With Disease Progression
The introduction of the tyrosine kinase inhibitors (TKIs) imatinib, dasatinib, and nilotinib has dramatically improved the treatment of chronic myeloid leukemia (CML). However, a minority of CML patie...
|
Thomas Ernst,
Andreas Hochhaus
|
58-66
|
|
|
|
Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: Novel Pathogenetic Lesions
Chronic myelomonocytic leukemia (CMML) and atypical chronic myeloid leukemia (aCML) are distinct, yet related, entities of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) characterized by morph...
|
Hideki Muramatsu,
Hideki Makishima,
Jaroslaw P. Maciejewski
|
67-73
|
|
|
|
Pathologic and Molecular Genetic Features of Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is an indolent B-cell leukemia. While many patients may not require therapy, some patients will suffer a progressive course and die of their disease. This clinical h...
|
Eric D. Hsi
|
74-79
|
|
|
|
Mutational Determinants of Epigenetic Instablity in Myeloid Malignancies
Until recently, myeloid neoplasms have been attributed to genomic and genetic instability leading to clonal outgrowth. However, it is now increasingly evident that epigenetic abnormalities also play a...
|
Anna M. Jankowska,
Hadrian Szpurka
|
80-96
|
|
|
|
p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies
Cytotoxic chemotherapy for acute myeloid leukemia (AML) usually produces only temporary remissions, at the cost of significant toxicity and risk for death. One fundamental reason for treatment failure...
|
Yogen Saunthararajah,
Pierre Triozzi,
Brian Rini,
Arun Singh,
Tomas Radivoyevitch,
Mikkael Sekeres,
Anjali Advani,
Ramon Tiu,
Frederic Reu,
Matt Kalaycio,
Ed Copelan,
Eric Hsi,
Alan Lichtin,
Brian Bolwell
et al.
|
97-108
|
|
|
|
Clinical Applications of Epigenetic Markers and Epigenetic Profiling in Myeloid Malignancies
Aberrant DNA methylation is frequent in the myeloid malignancies, particularly myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Promoter CpG methylation is correlated with silencin...
|
Michael A. McDevitt
|
109-122
|
|
|
|
Erratum
In the Current Clinical Practice column, “Variants of Uncertain Significance in Breast Cancer–Related Genes: Real-World Implications for a Clinical Conundrum. Part One: Clinical Genetics Recommendatio...
|
|
123
|
|
| Frontmatter |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Board
|
|
A1
|
|
|
|
Contents
|
|
A3-A4
|
|
|
|
Future and Previous Issues
|
|
A5
|
|
